Cystic Fibrosis

Study Outline

This study will evaluate the long-term safety and tolerability of elexacaftor (ELX, VX-445) in triple combination with tezacaftor (TEZ) and ivacaftor (IVA).

To find out if this trial is suitable for you please register below or contact our Clinical Trials Team at admin@resphealth.uwa.edu.au or phone 6151 0888.

Eligibility & Requirements

• Currently taking part in VX17-659-105 clinical trial.
• Aged 12 years or over but only 18 years or over at our site.
• Diagnosis of Cystic Fibrosis with a homozygous for the F508del (F/F) mutation or heterozygous for the F508del mutation and a minimal function mutation (F/MF).

What's Involved

• The total study duration is approximately 100 weeks (96 weeks for the Treatment Period, and 4 weeks for the Safety Follow-up Period). It involves  approximately 13 visits to the Institute for Respiratory Health at the QEII Medical Centre in Nedlands and approximately 14 phone calls.